Combination Therapy in Hypertension

Journal of Clinical Hypertension

Volumn 13, Issue 3, 2011, Pages 146-154

  Gradman, Alan H ^a   Basile, Jan N ^b   Carter, Barry L ^c   Bakris, George L ^d  

^a TEMPLE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^c UNIVERSITY OF IOWA   (United States)

^d UNIVERSITY OF CHICAGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; AMILORIDE; AMLODIPINE; ANGIOTENSIN RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CHLORTALIDONE; CLONIDINE; DIHYDROPYRIDINE; DILTIAZEM; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; FELODIPINE; HYDROCHLOROTHIAZIDE; HYDROCHLOROTHIAZIDE PLUS SPIRONOLACTONE; LOSARTAN; METHYLDOPA; METOPROLOL; PLACEBO; POTASSIUM SPARING DIURETIC AGENT; RAMIPRIL; SPIRONOLACTONE; TELMISARTAN; THIAZIDE DIURETIC AGENT; TRANDOLAPRIL PLUS VERAPAMIL; TRIAMTERENE; VALSARTAN; VERAPAMIL;

ADD ON THERAPY; ANTIHYPERTENSIVE ACTIVITY; ANTIHYPERTENSIVE THERAPY; ARTICLE; BLOOD PRESSURE REGULATION; BORDERLINE HYPERTENSION; BRADYCARDIA; CARDIAC PATIENT; CARDIOVASCULAR RISK; COMBINATION CHEMOTHERAPY; DIURETIC THERAPY; DRUG CHOICE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG FORMULATION; DRUG MEGADOSE; DRUG SAFETY; DRUG TOLERABILITY; EDEMA; FATIGUE; GLUCOSE INTOLERANCE; HEART BLOCK; HEART FAILURE; HEART INFARCTION; HUMAN; HYPERTENSION; HYPOKALEMIA; LOW DRUG DOSE; MONOTHERAPY; PATIENT COMPLIANCE; PATIENT SELECTION; PERIPHERAL EDEMA; PRIORITY JOURNAL; QUALITY OF LIFE; RISK REDUCTION; SEXUAL DYSFUNCTION; STROKE; TREATMENT OUTCOME;

EID: 79952161728     PISSN: 15246175     EISSN: 17517176     Source Type: Journal    
DOI: 10.1111/j.1751-7176.2010.00397.x     Document Type: Article

References (65)

1. Chobanian AV, Bakris GL, Black HR, et al. National high blood pressure education program coordinating committee: seventh report of the joint national committee on prevention, detection, evaluation, and treatment of high blood pressure. Hypertension. 2003;42:1206-1252.
2. The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC): 2007. Guidelines for the management of arterial hypertension. J Hypertens. 2007;25:1105-1187.
3. Williams B, Poulter NR, Brown MJ, et al. Guidelines for the management of hypertension: report of the fourth working party of the British Hypertension Society, 2004-BHSIV. J Hum Hypertens. 2004;18:139-185.
4. Mancia G, Laurent S, Agabati-Rosei E, et al. Reappraisal of European guidelines on hypertension management: a European Society of Hypertension Task Force document. J Hypertens. 2009;27:2121-2158.
5. Rosendorff C, Black HR, Cannon CP, et al. Treatment of hypertension in the prevention and management of ischemic heart disease: a scientific statement from the American Heart Association Council for High Blood Pressure Research and the Councils on Clinical Cardiology and epidemiology and Prevention. Circulation. 2007;115: 2761-2788.
6. Coleman TG, Hall JE. Systemic Hemodynamics and Regional Blood Flow Regulation. In: Izzo JL Jr, Black HR, Sica DA, eds. Hypertension Primer. 4th ed. Philadelphia, PA: Lippincott, Williams and Wilkins; 2008.
7. Law MR, Wald NJ, Morris JK, et al. Value of low dose combination treatment with blood pressure lowering drugs: analysis of 354 randomised trials. BMJ. 2003;326: 1427-1435.
8. Neaton JD, Grimm RH Jr, Prineas RJ, et al. Treatment of mild hypertension study. JAMA. 1993;270:713-724.
9. ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: the Antihypertensive and Lipid-lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA. 2002;288:2981-2997.
10. Hansson L, Zanchetti A, Carruthers SG, et al. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomized trial. Lancet. 1998;351:1755-1762.
11. Dahlöf B, Devereux RB, Kjeldsen SE, et al. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomized trial against atenolol. Lancet. 2002;359:995-1003.
12. Dickerson JE, Hingorani AD, et al. Optimisation of antihypertensive treatment by crossover rotation of four major classes. Lancet. 1999;353:2008-2013.
13. Mourad J, Waeber B, Zinnad F. Comparison of different therapeutic strategies in hypertension: a low-dose combination of perindopril/indapamide versus a sequential monotherapy or a stepped-care approach. J Hypertens. 2004;22:2379-2386.
14. Kotsis V, Stabouli S, Bouldin M, et al. Impact of obesity on 24-hour ambulatory blood pressure and hypertension. Hypertension. 2005;45:602-607.
15. Izzo R, deSimone G, Chinali M, et al. Insufficient control of blood pressure and incident diabetes. Diabetes Care. 2009;32:845-850.
16. Wald DS, Law M, Morris JK, et al. Combination therapy versus monotherapy in reducing blood pressure: meta-analysis on 11, 000 participants from 42 Trials. Am J Med. 2009;122:290-300.
17. Sica DA. Rationale for fixed-dose combinations in the treatment of hypertension: the cycle repeats. Drugs. 2002;62:243-262.
18. Gradman AH, Acevedo C. Evolving strategies for the use of combination therapy in hypertension. Curr Hypertens Rep. 2002;4:343-349.
19. Fung V, Huang J, Brand R, et al. Hypertension treatment in a medicare population: adherence and systolic blood pressure control. Clin Ther. 2007;29:972-984.
20. Dunbar-Jacob NHLBI Implementation Conference. 2009.
21. Bangalore S, Kamalakkannan G, Parkar S, et al. Fixed-dose combinations improve medication compliance: a meta-analysis. Am J Med. 2007;120:713-719.
22. Chrysant SG. Antihypertensive effectiveness of low-dose lisinopril hydrochlorothiazide combination. Arch Intern Med. 1994;154:737-743.
23. Chrysant SG, Fagan T, Glazer R, et al. Effects of benazepril and hydrochlorothiazide, given alone and in low- and high-dose combinations, on blood pressure in patients with hypertension. Arch Fam Med. 1996;5:17-24.
24. Pool J, Cushman WC, Saini RK, et al. Use of the factorial design and quadratic response surface models to evaluate the fosinopril and hydrochlorothiazide combination therapy in hypertension. Am J Hypertens. 1997;10:117-123.
25. Gradman AH, Kad R. Renin inhibition in hypertension. J Am Coll Cardiol. 2008;51:519-528.
26. Mackay JH, Arcuri KE, Goldberg AI, et al. Losartan and low-dose hydrochlorothiazide in patients with essential hypertension. Arch Intern Med. 1996;156:278-285.
27. Ambrosioni E, Borghi C, Costa FV. Captopril and hydrochlorothiazide: rationale for their combination. Br J Clin Pharmacol. 1987;23(suppl 1):43S-50.
28. Ernst ME, Carter BL, Goerdt CJ, et al. Comparative antihypertensive effects of hydrochlorothiazide and chlorthalidone on ambulatory and office blood pressure. Hypertension. 2006;47:352-358.
29. Frishman WH, Ram CVS, McMahon FG, et al. Comparison of amlodipine and benazepril monotherapy to amlodipine plus benazepril in patients with systemic hypertension: a randomized, double-blind, placebocontrolled, parallel-group study. J Clin Pharmacol. 1995;35: 1060-1066.
30. Philipp T, Smith TR, Glazer R, et al. Two multicenter, 8-week, randomized, double-blind, placebo-controlled, parallel-group studies evaluating the efficacy and tolerability of amlodipine and valsartan in combination and as monotherapy in adult patients with mild to moderate essential hypertension. Clin Ther. 2007;29:563-580.
31. Chrysant SG, Melino M, Karki S, et al. The combination of olmesartan medoxomil and amlodipine besylate in controlling high blood pressure: COACH, a randomized, double-blind, controlled, 8-week factorial efficacy and safety study. Clin Ther. 2008;30:587-604.
32. Gradman AH, Cutler NR, Davis PJ, et al. Combined enalapril and felodipine extended release (ER) for systemic hypertension. Am J Cardiol. 1997;79:431-435.
33. Jamerson K, Weber MA, Bakris GL, et al; for the ACCOMPLISH Trial Investigators. Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients. N Engl J Med. 2008; 359:2417-2428.
34. Weber MA, Bakris GL, Dahlöf B, et al; for the ACCOMPLISH Investigators. Baseline characteristics in the Avoiding Cardiovascular events through Combination therapy in Patients Living with Systolic Hypertension (ACCOMPLISH) trial: a hypertensive population at high cardiovascular risk. Blood Press. 2007;16:13-19.
35. Yusuf S, Teo KK, Pogue J, et al. Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med. 2008;358:1547-1559.
36. Oparil S, Yarows SA, Patel S, et al. Efficacy and safety of combined use of aliskiren and valsartan in patients with hypertension: a randomised double-blind trial. Lancet. 2007;370:221-229.
37. Salvetti A, Magagna A, Innocenti P, et al. The combination of chlorthalidone with nifedipine does not exert an additive antihypertensive effect in essential hypertensives: a crossover multicenter study. J Cardiovasc Pharmacol. 1991;17:332-335.
38. Weir MR, Weber MA, Punzi HA, et al. A dose escalation trial comparing the combination of diltiazem SR and hydrochlorothiazide with the monotherapies in patients with essential hypertension. J Hum Hypertens. 1992;6: 133-138.
39. Julius S, Kjeldsen SE, Weber M, et al; for the VALUE Trial Group. Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: theVALUE randomised trial. Lancet. 2004;363:2022-2031.
40. Carlberg B, Samuelsson O, Lindholm LH. Atenolol in hypertension: is it a wise choice? Lancet. 2004;364:1684-1689.
41. Lindholm LH, Carlberg B, Samuelsson O. Should b blockers remain first choice in the treatment of primary hypertension? A meta-analysis. Lancet. 2005;366:1545-1553.
42. Bradley HA, Wiysonge CS, Volmink JA, et al. How strong is the evidence for use of beta-blockers as first-line therapy for hypertension? Systematic review and meta-analysis. J Hypertens. 2006;24:2131-2141.
43. Saunders E, Weir MR, Kong BW, et al. A comparison of the efficacy and safety of a beta blocker, a calcium channel blocker, and a converting enzyme inhibitor in hypertensive blacks. Arch Intern Med. 1990;150:1707-1713.
44. Frishman WH, Bryzinski BS, Coulson LR, et al. Amultifactorial trial design to assess combination therapy in hypertension. Arch Intern Med. 1994;154:1461-1468.
45. Bateman DN, Dean CR, Mucklow JC, et al. Atenolol and chlorthalidone in combination for hypertension. Br J Clin Pharmacol. 1979;7:357-363.
46. Lacourcière Y, Arnott W. Placebo-controlled comparison of the effects of nebivolol and low-dose hydrochlorothiazide as monotherapies and in combination on blood pressure and lipid profile in hypertensive patients. J Hum Hypertens. 1994;8:283-288.
47. Gradman AH. Drug Combinations. In: Izzo JL Jr, Black HR, Sica DA, eds. Hypertension Primer. 4th ed. Philadelphia PA: Lippincott, Williams, and Wilkins; 2008.
48. Siscovick DS, Raghunathan TE, Psaty BM, et al. Diuretic therapy for hypertension and the risk of primary cardiac arrest. N Engl J Med. 1994;330:1852-1857.
49. Calhoun DA. Resistant or difficult-to-treat hypertension. J Clin Hypertens. 2006;8:181-186.
50. Myers MG. Hydrochlorothiazide with or without amiloride for hypertension in the elderly: a dose-titration study. Arch Intern Med. 1987;147:1026-1030.
51. Guerrero P, Fuchs FD, Moreria LM. Blood pressure-lowering efficacy of amiloride versus enalapril as add-on drugs in patients with uncontrolled blood pressure receiving hydrochlorothiazide. Clin Exp Hypertens. 2008;30: 553-564.
52. Khosla N, Kalaitzidis R, Bakris GL. Predictors of hyperkalemia risk following hypertension control with aldosterone blockade. Am J Nephrol. 2009;30:418-424.
53. Dahlöf B, Degl' Innocenti A, Elmfeldt D, et al. Felodipine-metoprolol combination tablet: maintained health-related quality of life in the presence of substantial blood pressure reduction. Am J Hypertens. 2005;18:1313-1319.
54. Frishman WH, Hainer JW, Sugg J; M-FACT Study Group. A factorial study of combination hypertension treatment with metoprolol succinate extended release and felodipine extended release: results of the Metoprolol Succinate-Felodipine Antihypertension Combination Trial (M-FACT). Am J Hypertens. Am J Hypertens. 2006;19: 388-395.
55. Wing LMH, Chalmers JP, West MJ, et al. Enalapril and atenolol in essential hypertension: attenuation of hypertensive effects in combination. Clin Exp Hypertens. 1988;10:119-133.
56. Mehta JL, Lopez LM. Rebound hypertension following abrupt cessation of clonidine and metoprolol. Treatment with labetalol. Arch Intern Med. 1987;147:389-390.
57. Weber MA, Julius S, Kjeldsen SE, et al. Blood pressure dependent and independent effects of antihypertensive treatment on clinical events in the VALUE Trial. Lancet. 2004;363:2049-2051.
58. Pepine CJ, Handberg EM, Cooper-DeHoff RM, et al. A calcium antagonist vs a non-calcium antagonist hypertension treatment strategy for patients with coronary artery disease. The International Verapamil-Trandolapril Study (INVEST): a randomized controlled trial. JAMA. 2003; 290:2805-2816.
59. Mancia G, Messerli F, Bakris G, et al. Blood pressure control and improved cardiovascular outcomes in the International Verapamil SR-Trandolapril Study. Hypertension. 2007;50:299-305.
60. Weir M, Levy D, Crikelair N, et al. Time to achieve blood-pressure goal: influence of dose of valsartan monotherapy and valsartan and hydrochlorothiazide combination therapy. Am J Hypertens. 2007;20:807-815.
61. Jamerson K, Bakris GL, Dahlöf B, et al; for the ACCOMPLISH Investigators. Exceptional early blood pressure control rates: the ACCOMPLISH trial. Blood Press. 2007;16:80-86.
62. Feldman RD, Zou GY, Vandervoort MK, et al. A simplified approach to the treatment of uncomplicated hypertension: a cluster randomized, controlled trial. Hypertension. 2009;53:646-653.
63. Dezii CM. A retrospective study of persistence with single-pill combination therapy vs. concurrent two-pill therapy in patients with hypertension. Manag Care. 2000; 9(suppl):2-6.
64. Egan BM. Fixed-dose combinations and hypertension control in community-based practices: application of the "keep-it-simple" principle. Hypertension. 2009;53:598-599.
65. Carter BL, Bergus GR, Dawson JD. Evaluate physician/pharmacist collaboration to improve blood pressure control. J Clin Hypertens. 2008;10:260-271.